CAPRICOR THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $385.21M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | – | $-0.70 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | – | $-0.59 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | After market close | $0 | $-0.62 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | $0 | $-0.54 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | $0 | $-0.57 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | $0 | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 19, 2025 | After market close | $11.10M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | After market close | $2.30M | $-0.38 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | After market close | – | – | – |
Press releases
Announcements Capricor Therapeutics filed with the SEC
Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
Other events · EX-99.1 to Form 8-K
Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
Other events · EX-99 to Form 8-K
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
Other events · EX-99.1 to Form 8-K
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
medicine and to find a way to make people’s lives better and longer. She earned her Ph.D. in
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside
Regulation FD disclosure · EX-99.1 to Form 8-K
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Regulation FD disclosure · EX-99.1 to Form 8-K
Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Regulation FD disclosure · EX-99.1 to Form 8-K
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Regulation FD disclosure · EX-99.1 to Form 8-K
Capricor Therapeutics, Inc. NASDAQ: CAPR
Regulation FD disclosure · EX-99.2 to Form 8-K
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
WͲϭϬϬϮ D WƌŽŐƌĂŵ ϭϬϬϮ D WƌŽŐ
Regulation FD disclosure · EX-99.1 to Form 8-K
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Announces $23 Million Registered Direct Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Reports Third Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Reports Second Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of
Other events · EX-99.1 to Form 8-K